Radermecker, Marc ; Université de Liège - ULiège > Chirurgie cardio-vasculaire
de Leval, Laurence ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques - Département des sciences biomédicales et précliniques
Connoly HM, Crary JL, Mc Goon MD, et al.- Valvular heart disease associated with fenfluramine. N Engl J Med, 1997, 337, 581-588.
Graham DJ, Green L.- Further cases of valvular heart disease associated with fenfluramine. N Engl J Med, 1997, 337, 635.
Brenot F, Herve P, Petitpretz P, et al.- Primary pulmonary hypertension and fenfluramine use. Br Heart J, 1993, 70, 537-541.
Thomas SH, Butt AY, Corris PA, et al.- Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Br Heart J, 1995, 74, 660-663.
Abenhaim L, Moride Y, Brenot F, et al. for the International Primary Pulmonary Hypertension Study Group.- Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med, 1996, 335, 609-616.
Adams C, Cohen A.- Atteintes valvulaires des anorexigènes. Arch mal coeur et vaiss, 1999, 92, 1213-1219.
Volmar KE, Hutchins GM.- Aortic and mitral fenfluramine- phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med, 2001, 125, 1555-1561.
Gustafsson BI. Tommeras K. Nordrum I, et al.- Long-term serotonin administration induces heart valve disease in rats. Circulation, 2005, 111, 1517-1522.
Jick H, Vasilakis C, Weinrauch LA, et al.- A population- based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med, 1998, 339 (11), 719-724. (Pubitemid 28417354)
Jollis JG, Landolfo CK, Kisslo J, et al.- Fenfluramine and phentermine and cardiovascular findings : Effect of treatment duration on prevalence of valve abnormalities. Circulation, 2000, 101, 2071-2077.
Lepor NE, Gross SB, Daley WL, et al.- Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol, 2000, 86, 107-110.
Mast ST, Jollis JG, Ryan T, et al.- The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Int Med, 2001, 134, 261-266.
Weissman NJ, Panza JA, Tighe JF, et al.- Natural history of valvular regurgitation 1 year after discontinuation of Dexfenfluramine Therapy. A randomized, Double-Blind, Placebo-Controlled Trial. Ann Int Med, 2001, 134, 267-273.
Greffe G, Chalabreysse L, Mouly-Bertin C, et al.- Valvular Heart Disease Associated With Fenfluramine Detected 7 Years After Discontinuation of Treatment. Ann Thorac Surg, 2007, 83, 1541-1543.
